A pickup in M&A activity is always a bull thesis for biotech investors, especially after what Jefferies analyst Michael Yee called «
a relatively lackluster year for biopharma M&A» in 2017.
With Americans tuning in to watch the league for the first time on the commercial broadcasting station, last
year's leading goalscorer put the visitors ahead after what was otherwise a
relatively lackluster start to the David Moyes era in Manchester.